Background Early prediction of lamivudine (LAM) response by individualized monitoring of
serum HBV DNA like roadmap concept, and investigation of the outcome after LAM …

BACKGROUND:: Limited data are available on the clinical course of hepatitis B virus (HBV)
infection after discontinuation of lamivudine prescribed for kidney or heart …

BACKGROUND:: Following renal transplantation (RT), chronic immunosuppression is
associated in hepatitis B virus (HBV)(+) patients with a flare-up of the disease, which might …

Background Chronic hepatitis B virus (HBV) infection is an important cause of morbidity and
mortality in renal-transplant recipients. The aim of the study was to assess the efficacy and …

Background Lamivudine is a potent inhibitor of hepatitis B virus (HBV) replication. As other
available HBV therapies, its efficacy is hampered by relapse after discontinuation and by the …

Background. Chronic hepatitis B virus (HBV) infection increases morbidity and mortality in
renal transplant recipients (RTR). Lamivudine has shown promising results in patients with …

Introduction Immunosuppressive therapy after renal transplantation stimulates the
replication of hepatitis B virus (HBV) and may lead to accelerated chronic liver disease …

AIM: To analyze the effectiveness and safety of lamivudine treatment in patients with chronic
HBV infection undergoing hemodialysis or after kidney transplantation, and to study the …

Hepatitis B surface antigen (HBsAg)-positive kidney transplant recipients have increased
liver-related mortality. The impact of lamivudine treatment on patient survival, the optimal …

Background. The aim of this pilot study was to evaluate the efficacy and the safety of
lamivudine therapy in hepatitis B virus (HBV)-positive/DNA-positive renal transplant …